-
公开(公告)号：US20190054168A1
公开(公告)日：2019-02-21
申请号：US16176743
申请日：2018-10-31
IPC分类号： A61K39/395 , C07K17/02 , C07K14/005 , C07K16/10 , A61K39/12 , A61K39/00
摘要： Immunogenic influenza hemagglutinin-derived peptide compositions described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide compositions comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein bound to an immunogenic carrier protein, such as an influenza hemagglutinin (HA) protein (i.e., full length HA), and the like. The immunogenic peptide compositions described herein can be utilized to treat or prevent influenza infection and to prepare influenza-specific therapeutic antibodies that interfere with influenza virus-host cell membrane fusion. The peptide conjugates can be formulated in pharmaceutical compositions useful for broad spectrum treatment or prevention of influenza infections
-
2.发明申请公开(公告)号：US20170258902A1
公开(公告)日：2017-09-14
申请号：US15591386
申请日：2017-05-10
IPC分类号： A61K39/395 , C07K17/02
CPC分类号： A61K39/3955 , A61K39/12 , A61K2039/6081 , C07K14/005 , C07K16/1018 , C07K17/02 , C07K2317/33 , C12N2760/16122 , C12N2760/16134
摘要： Immunogenic influenza hemagglutinin-derived peptide conjugates described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide conjugates comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein conjugated to an immunogenic carrier protein, such asbovine serum albumin (BSA), an influenza hemagglutinin (HA) protein (i.e., full length HA), and the like. The immunogenic peptide conjugates described herein can be utilized to treat or prevent influenza infection and to prepare influenza-specific therapeutic antibodies that interfere with influenza virus-host cell membrane fusion. The peptide conjugates can be formulated in pharmaceutical compositions useful for broad spectrum treatment or prevention of influenza infections.
-
公开(公告)号：US20160129110A1
公开(公告)日：2016-05-12
申请号：US14802247
申请日：2015-07-17
发明人： Robert Francis GARRY , Luis Manuel BRANCO , Bruce Alan BUNNELL , Russell B. WILSON , Samuel E. HOPKINS
CPC分类号： A61K39/42 , A61K35/28 , C07K16/10 , C07K2317/76 , C12N5/0667 , C12N2510/00 , G01N33/6854 , Y02A50/387 , Y02A50/389 , Y02A50/393 , Y02A50/395 , Y02A50/402 , Y02A50/406 , Y02A50/409 , Y02A50/411 , Y02A50/421 , Y02A50/423 , Y02A50/463 , Y02A50/465 , Y02A50/469 , Y02A50/471 , Y02A50/475 , Y02A50/478 , Y02A50/48 , Y02A50/481 , Y02A50/491
摘要： Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFNα, IFNβ, or IFNω), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
摘要翻译： 本文描述了附加表达特异性靶向病原体（例如病毒，细菌或寄生虫）或毒素的感染物种的多种免疫反应性多肽的免疫保护性原代间充质干细胞（IP-MSC）。 IP-MSC表达两种或更多种（例如，2至约100）免疫反应性多肽（例如，全抗体，单链抗体（ScFV），Fab或F（ab）2抗体片段，双抗体，抗体等） ，和任选的一种或多种其它免疫调节多肽，例如细胞因子如白细胞介素（例如IL-2，IL-4，IL-6，IL-7，IL-9和IL-12），干扰素 例如IFNα，IFN和bgr，或IFNω）等，其可增强免疫反应性多肽的有效性。
-
公开(公告)号：US20140271580A1
公开(公告)日：2014-09-18
申请号：US13826285
申请日：2013-03-14
发明人： Robert Francis GARRY , Luis Manuel BRANCO , Bruce Alan BUNNELL , Russell B. WILSON , Samuel E. HOPKINS
IPC分类号： A61K35/28
CPC分类号： A61K39/42 , A61K35/28 , C07K16/10 , C07K2317/76 , C12N5/0667 , C12N2510/00 , G01N33/6854 , Y02A50/387 , Y02A50/389 , Y02A50/393 , Y02A50/395 , Y02A50/402 , Y02A50/406 , Y02A50/409 , Y02A50/411 , Y02A50/421 , Y02A50/423 , Y02A50/463 , Y02A50/465 , Y02A50/469 , Y02A50/471 , Y02A50/475 , Y02A50/478 , Y02A50/48 , Y02A50/481 , Y02A50/491
摘要： Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFNα, IFNβ, or IFNω), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
摘要翻译： 本文描述了附加表达特异性靶向病原体（例如病毒，细菌或寄生虫）或毒素的感染物种的多种免疫反应性多肽的免疫保护性原代间充质干细胞（IP-MSC）。 IP-MSC表达两种或更多种（例如，2至约100）免疫反应性多肽（例如，全抗体，单链抗体（ScFV），Fab或F（ab）2抗体片段，双抗体，抗体等） ，和任选的一种或多种其它免疫调节多肽，例如细胞因子如白细胞介素（例如IL-2，IL-4，IL-6，IL-7，IL-9和IL-12），干扰素 例如IFNα，IFN和bgr，或IFNω）等，其可增强免疫反应性多肽的有效性。
-
公开(公告)号：US20210401984A1
公开(公告)日：2021-12-30
申请号：US17477725
申请日：2021-09-17
发明人： Robert Francis GARRY , Luis Manuel BRANCO , Bruce Alan BUNNELL , Russell B. WILSON , Samuel E. HOPKINS
IPC分类号： A61K39/42 , A61K35/28 , C12N5/0775 , C07K16/10 , G01N33/68
摘要： Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The immunoreactive polypeptides can be, e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like). Optionally IP-MSC are trasfected to express one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFNα, IFβ, or IFNω), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.
-
6.发明申请IMMUNOGENIC PEPTIDE CONJUGATE AND METHOD FOR INDUCING AN ANTI-INFLUENZA THERAPEUTIC ANTIBODY RESPONSE THEREWITH 有权免疫球蛋白结合蛋白和诱导抗流感病毒抗体反应的方法公开(公告)号：US20140271650A1
公开(公告)日：2014-09-18
申请号：US13828988
申请日：2013-03-14
IPC分类号： A61K39/395 , A61K39/145 , C07K17/02
CPC分类号： A61K39/3955 , A61K39/12 , A61K2039/6081 , C07K14/005 , C07K16/1018 , C07K17/02 , C07K2317/33 , C12N2760/16122 , C12N2760/16134
摘要： Immunogenic influenza hemagglutinin-derived peptide conjugates described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide conjugates comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein conjugated to an immunogenic carrier protein, such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), an influenza hemagglutinin (HA) protein (i.e., full length HA), and the like. The immunogenic peptide conjugates described herein can be utilized to treat or prevent influenza infection and to prepare influenza-specific therapeutic antibodies that interfere with influenza virus-host cell membrane fusion. The peptide conjugates can be formulated in pharmaceutical compositions useful for broad spectrum treatment or prevention of influenza infections.
摘要翻译： 本文所述的免疫原性流感血凝素衍生的肽缀合物诱导针对流感病毒的特异性治疗性抗体应答。 免疫原性肽缀合物包含与免疫原性载体蛋白缀合的流感血凝素蛋白的融合起始区（FIR）结构域，例如钥孔血蓝蛋白（KLH），牛血清白蛋白（BSA），流感血凝素（HA） 蛋白质（即，全长HA）等。 本文所述的免疫原性肽缀合物可用于治疗或预防流感感染并制备干扰流感病毒宿主细胞膜融合的流感特异性治疗性抗体。 肽缀合物可以配制成用于广谱治疗或预防流感感染的药物组合物中。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.018 秒)
